Advances in LDL-C Reduction: A Strategic Look
at the Effectiveness of PCSK9 Inhibitors

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2017 to December 31, 2017

Instructions for CME/CNE: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Amgen and Sanofi US Regeneron Pharmaceuticals Alliance

Description
Current guidelines agree that LDL-C is a major factor in the development of cardiovascular disease (CVD). In addition, it is well established that lowering LDL-C in high-risk patients reduces the risk for CVD. Primary prevention promotes lifestyle behaviors to prevent the development of accelerating risk factors as well as elevated LDL-C. Statins have typically been the first-line therapy and the choice of statins depends on availability, costs, and tolerability. In patients who are statin intolerant, several options are available and genetic insights into the study of LDL-C levels have expanded potential targets of drug therapy and led to the development of novel therapeutic agents. Among them are modulators containing lipoproteins production and proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors. Despite significant advances in the number of treatment options for advanced LDL-C management, there is a clear need for better education and the understanding of these new and emerging therapies that will improve outcomes.

Upon Completion of this activity, participants will be able to:

  • Analyze updated AHA/ACC/NLA guidelines and recommendations for current therapeutic options to achieve lower LDL-C levels

  • Explore the mechanisms of action in LDL production and the role of PCSK9 in homeostasis of LDL-C

  • Assess the safety and efficacy on the latest clinical trial data for the novel LDL-C lowering agents, PCSK9 inhibitors, and their potential application to address cardiovascular risk in clinical practice

  • Discuss the emerging evidence on novel pathways and biologics and their therapeutic significance in the development of novel LDL targets

  • Evaluate the challenges and benefits of novel agents, including the role of PCSK9 inhibitors in the management of LDL-C reduction
     

Faculty: R. Scott Wright, MD
Professor of Medicine
Mayo Clinic

Disclosure:

Dr. Wright serves on an advisory board/panel for Boehringer Ingelheim and Sanofi-Regeneron and receives research support from AstraZeneca, the Medicines Company, and Pfizer. His presentations have been peer reviewed.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This presentation is supported by educational grants from
Amgen and Sanofi US Regeneron Pharmaceuticals Alliance

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue